Core Insights - The company, Goss, announced the publication of clinical I/IIa study results for its KRAS G12C inhibitor, Glecirasib, in combination with SHP2 inhibitor, JAB-3312, in the prestigious medical journal, The Lancet Respiratory Medicine, marking the first systematic clinical data for this dual oral therapy to be featured in such a high-impact publication [1] Group 1 - The open-label clinical I/IIa study was conducted in China, enrolling 171 patients with KRAS G12C mutated non-small cell lung cancer (NSCLC), including 102 treatment-naive patients [1] - The combination therapy achieved a 71% objective response rate (ORR) and a median progression-free survival (mPFS) of 12.2 months in first-line patients, demonstrating a leading standard in KRAS G12C related first-line treatment [1] - Compared to the current standard treatment of immunotherapy plus chemotherapy, this chemotherapy alternative shows a highly competitive profile [1] Group 2 - Currently, KRAS G12C inhibitors and SHP2 inhibitors are undergoing phase III clinical trials in China, directly comparing this combination therapy with existing standard treatment pathways in first-line patients [2] - This dual oral combination is positioned to potentially become the first SHP2 combination therapy to receive global approval [2]
加科思-B(01167.HK)：KRAS G12C与SHP2联合疗法数据见刊《柳叶刀呼吸医学》